

IMS Health Announces Pricing of Initial Public Offering

Written by Australian Business

DANBURY, Conn.--([BUSINESS WIRE](#))--IMS Health Holdings, Inc. ("IMS Health") today announced the pricing of its initial public offering of 65,000,000 shares of its common stock at an initial public offering price to the public of \$20.00 per share, including 52,000,000 shares to be sold by IMS Health and 13,000,000 shares to be sold by selling shareholders. In addition, the selling shareholders have granted the underwriters a 30-day option to purchase up to an additional 9,750,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

IMS Health expects to use substantially all of the net proceeds from the shares offered by it to repay existing long-term debt. IMS Health will not receive any of the proceeds from the sale of shares by the selling shareholders.

The offering is expected to close on April 9, 2014, subject to customary closing conditions. The shares are expected to begin trading on The New York Stock Exchange on April 4, 2014 under the ticker symbol "IMS."

J.P. Morgan Securities LLC, Goldman, Sachs & Co., and Morgan Stanley & Co. LLC are acting as joint book-running managers and as representatives of the underwriters for the offering. In addition, BofA Merrill Lynch, Barclays, Deutsche Bank Securities, and Wells Fargo Securities are joint book-running managers for the offering and TPG Capital BD, LLC, HSBC, SunTrust Robinson Humphrey, Mizuho Securities, RBC Capital Markets, Piper Jaffray, William Blair, Drexel Hamilton, Leerink Partners and Stifel are acting as co-managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 3, 2014. The offering is being made only by means of the written prospectus forming part of the effective registration statement. Copies of the final prospectus relating to this offering, when available, may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, facsimile at (212) 902-9316, or e-mail at prospectus-ny@ny.email.gs.com; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About IMS Health

IMS Health is a leading global information and technology services company providing clients in the healthcare industry with comprehensive solutions to measure and improve their performance. By applying sophisticated analytics and proprietary application suites hosted on the *IMS One* intelligent cloud, the company connects more than 10 petabytes of complex healthcare data on diseases, treatments, costs and outcomes to help its clients run their operations more efficiently. Drawing on information from 100,000 suppliers, and on insights from more than 45 billion healthcare transactions processed annually, IMS Health's approximately 9,500 employees drive results for healthcare clients globally. Customers include pharmaceutical, consumer health and medical device manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community.

Cautionary Note Regarding Forward-Looking Statements

Any statements in this release that are not historical or current facts are forward-looking statements. Forward-looking statements convey IMS Health's current expectations or forecasts of future events. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause IMS Health's actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Certain of these risks and uncertainties are described in the "Risk factors" and "Cautionary note regarding forward-looking statements" section of the Registration Statement on Form S-1. Unless required by law, IMS Health undertakes no obligation to publicly update or revise any forward-looking statements to reflect circumstances or events after the date of this press release.

IMSFIN

IMS Health Announces Pricing of Initial Public Offering

Written by Australian Business

[Read more](#)